424B5 filed Aug 10, 2026 at 17:03 ET
Silence Therapeutics is conducting a $150M underwritten public offering of ADSs, announced concurrently with positive Phase 2 SANRECO topline results for divesiran in polycythemia vera. The offering represents significant dilution (~27% of current market cap) but capitalizes on the stock's recent catalyst-driven appreciation to fund Phase 3 development. The net tangible book value was $27.7M ($0.59/ADS) as of June 30, 2026, and the offering will cause substantial dilution to new investors, though exact per-ADS dilution is not calculable as the offering price is not yet set.